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ABSTRACT
S100A4 (metastasin-1), a metastasis-associated protein and marker of the 
epithelial to mesenchymal transition, contributes to several hallmarks of cancer and 
has been implicated in the progression of several types of cancer. However, the impacts 
of S100A4 signaling in lung cancer progression and its potential use as a target for 
therapy in lung cancer have not been properly explored. Using established lung cancer 
cell lines, we demonstrate that S100A4 knockdown reduces cell proliferation, invasion 
and three-dimensional invasive growth, while overexpression of S100A4 increases 
invasive potential. In patient-derived tissues, S100A4 is preferentially elevated in 
lung adenocarcinoma. This elevation is associated with lymphovascular invasion and 
decreased overall survival. In addition, depletion of S100A4 by shRNA inhibits NF-
κB activity and decreases TNFα-induced MMP9 expression. Furthermore, inhibition 
of the NF-κB/MMP9 axis decreases lung carcinoma invasive potential. Niclosamide, 
a reported inhibitor of S100A4, blocks expression and function of S100A4 with a 
reduction in proliferation, invasion and NF-κB-mediated MMP9 expression. Collectively, 
this study highlights the importance of the S100A4/NF-κB/MMP9 axis in lung cancer 
invasion and provides a rationale for targeting S100A4 to combat lung cancer.
INTRODUCTION
A majority of lung cancer patients present at an 
advanced stage, which often precludes treatment with 
surgical resection alone [1]. Non-small cell lung cancer 
(NSCLC) accounts for roughly 85% of all lung cancers, 
and includes multiple histologic subtypes such as 
adenocarcinoma (ADC) and squamous cell carcinoma 
(SCC). Despite recent advances in screening and therapy, 
the prognosis for NSCLC remains poor, with only 15% of 
patients surviving five years after diagnosis [1]. A number 
of targeted agents show promise for the treatment of 
NSCLC, however, patients with advanced disease often 
develop resistance to these therapies [2, 3]. Therefore, 
there is an urgent need to better understand the crucial 
drivers of the metastatic process and to explore and 
develop novel therapeutic agents to reduce the morbidity 
and mortality associated with NSCLC.
S100A4 (also known as metastasin-1 (mts1)/fibroblast 
specific protein (FSP1)) is a calcium binding EF-hand 
protein that has been implicated in carcinoma progression 
and is a marker of the epithelial to mesenchymal transition 
Oncotarget34631www.impactjournals.com/oncotarget
(EMT) [4–6]. S100A4 has been identified in the nucleus, 
cytoplasm and extracellular space, suggesting that it signals 
through both intracellular and extracellular mechanisms 
[7]. Intracellular S100A4 interacts with a number of target 
proteins, such as p53, [8] and the heavy chain of non-muscle 
myosin IIA (MHC-IIA) [9]. We have shown that S100A4 
interacts with Rhotekin to facilitate the formation of cell 
membrane protrusions and promote invasive growth in 
carcinoma cells [7]. S100A4 is secreted by both cancer and 
stromal cells to participate in both paracrine and autocrine 
signaling through its putative receptor RAGE, as well as 
through EGFR- and Toll-like receptor-4 (TLR-4)-mediated 
pathways. S100A4 can also activate NF-κB, thus stimulating 
a pathway that promotes proliferation and cell survival in 
multiple tumor types [10]. Collectively, through these 
intracellular and extracellular actions, S100A4 contributes 
to several hallmarks of cancer, including cell survival and 
proliferation, angiogenesis, invasion and metastasis, and 
tumor-promoting inflammation [11, 12]. Through these 
extensive biological functions, S100A4 expression is 
associated with tumor progression and is identified as a 
prognostic indicator in many human malignancies [6].
Despite extensive investigation of S100A4 in 
carcinoma progression, the impact of S100A4 signaling 
in lung cancer is poorly defined. In this study, we 
investigated the contribution of S100A4 in lung cancer 
cell invasion, determined the clinical significance of 
S100A4 expression in patient-derived lung cancer tissues, 
and provided a rational for targeting S100A4 signaling 
through repurposing an FDA-approved drug.
RESULTS
S100A4 drives the invasive potential of lung 
cancer cells
We used a panel of established lung cancer cell lines 
with different genetic backgrounds (Supplementary Table 
1) to examine S100A4 expression in lung cancer cells by 
immunoblot (Figure 1A) and Q-PCR (Figure 1B). S100A4 
was highly expressed in about 50% of cell lines tested 
(Supplementary Table 1). Culturing cells in 3D Matrigel 
is commonly used to assess physiologically relevant 
tumorigenesis, morphogenesis and invasive potential [13, 
14]. To test the contribution of S100A4 to lung cancer cell 
proliferation and invasive potential, loss-of function and 
gain-of function studies were performed in combination 
with 3D Matrigel analyses. S100A4 was depleted in 
A549 and H460 cells using lentiviral-based shRNA. 
Cells were grown in 3D Matrigel with growth media 
containing 2% FBS. Efficient knockdown of S100A4 in 
A549 cells (Figure 1C and 1D) dramatically decreased cell 
proliferation (Figure 1E) and invasive growth in the 3D 
Matrigel (Figure 1F and 1G). Similar results were observed 
in H460 cells (Supplementary Figure 1) and H358 cells 
(Supplementary Figure 2). In contrast, overexpression 
of S100A4 in H1299 cells promoted cell invasion and 
invasive growth in the 3D system (Figure 1H-1J) but did 
not increase cell proliferation (data not shown), suggesting 
that the effect of S100A4 in promoting proliferation is cell 
context-dependent. Collectively, these data demonstrate 
that S100A4 drives an invasive phenotype in lung cancer 
cells.
S100A4 is overexpressed in patient-derived 
lung adenocarcinomas and associates with poor 
prognosis
We constructed a lung cancer tissue microarray 
(TMA) and stained sections for S100A4 using 
immunohistochemistry in order to examine S100A4 
expression in patient-derived tissues (N = 212). A 
wide range of staining intensities was observed in 
lung carcinoma cells, which were scored using a semi-
quantitative scale ranging from 0 to 3 (Figure 2). In 
addition, positive staining was observed in lymphocytes 
and macrophages, which served as positive internal 
controls (data not shown). Next, we correlated S100A4 
expression with clinical and pathological features. We 
found that S100A4 was preferentially overexpressed in 
lung adenocarcinoma when compared to squamous cell 
carcinoma (Figure 3A), which was confirmed using a 
publicly available gene expression dataset (Figure 3B). 
S100A4 overexpression was much less common among 
the other histologic subtypes as only 9.7% of these 
samples exhibited elevated levels of S100A4 expression 
(Supplementary Table 2). Furthermore, we found that 
S100A4 overexpression was associated with the presence 
of lymphovascular invasion (Table 1) and decreased 
overall survival among patients with lung adenocarcinoma 
(Figure 3C; median survival: 29.5 versus 70 months, 
hazard ratio 2.62, 95% confidence interval 1.133 to 6.035, 
P = 0.0243). When all histologic subtypes were combined, 
there was no significant difference in median survival 
between patients with and without S100A4 overexpression 
(Figure 3D; hazard ratio 1.220, 95% confidence interval 
0.6904 to 2.157, P = 0.4692). This observation suggests 
that S100A4 overexpression has a higher impact in the 
lung adenocarcinoma subpopulation when compared to 
the squamous cell carcinoma subpopulation.
Niclosamide, an FDA-approved drug, targets 
S100A4 to abbrogate the invasive potential of 
lung cancer cells
Niclosamide affects multiple signaling pathways 
that are important in cancer progression and has also 
been shown to block S100A4 expression in colon cancer 
cells [15, 16]. Our data show that S100A4 drives an 
invasive phenotype in lung cancer cells (Figure 1), thus 
positioning S100A4 as a potential target for the treatment 
of advanced NSCLC. Therefore, we investigated whether 
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niclosamide also suppresses S100A4 expression in lung 
cancer cells and whether it inhibits S100A4-mediated 
functions. Niclosamide blocked S100A4 expression in 
lung carcinomas both at the mRNA (Figure 4A) and 
protein levels (Figure 4B) in a dose-dependent manner. 
This inhibitory effect of niclosamide on lung cancer cell 
proliferation was also investigated using H358 and A549 
cells treated with varied concentrations of niclosamide. 
We performed direct cell count or MTT assay to assess the 
number of viable cells over 3-5 days. Niclosamide treatment 
dramatically decreased the proliferation of H358 cells 
(Figure 4C) and A549 cells (Figure 4D), at concentrations as 
low as 0.5 μM. We then evaluated the effect of niclosamide 
treatment on the invasive capacity of A549 cells using 
Transwell invasion assays and by monitoring invasive 
growth in the 3D Matrigel system. As visualized in Figure 
4E, niclosamide treatment decreased EGF-stimulated 
A549 cell invasion. Consistent with these observed effects 
on proliferation and invasion, niclosamide significantly 
inhibited invasive growth in the 3D Matrigel (Figure 4F 
and 4G). These data demonstrate that niclosamide blocks 
the invasive capabilities of lung cancer cells driven by 
Figure 1: S100A4 drives the invasive potential of lung cancer cells. A and B. Lung cancer cells as indicated were lysed in RIPA 
buffer, total cell lysates (80μg) were subjected to 15% SDS-PAGE, transferred and immunoblotted with rabbit anti-S100A4 antibody (A). 
RNA was isolated from cells and quantitative real time PCR (Q-PCR) was used to assess S100A4 expression levels (B). C-G. A549 cells 
with stable knockdown of S100A4 by shRNA targeting S100A4 (shS100A4) or expressing a non-targeting control (shCont) were generated. 
S100A4 expression was assessed by immunoblot analysis (C) and Q-PCR (D). Cell proliferation in standard (2D) culture was assessed by 
MTT (E). Cells were grown in 3D Matrigel for 5 days and representative phase contrast images for control and knockdown cells are shown 
(F). The diameter of 70-120 colonies from randomly chosen fields was measured, quantified for average colony volume and presented in 
(G). H-J. H1299 cells, stably transfected with pIRES-GFP-S100A4 (GFP-S100A4) or pIRES-GFP alone (GFP), were assessed for S100A4 
expression by immunoblot analysis (H) or for invasion toward 1% FBS overnight (I) or grown in 3D Matrigel for 5 days (J). Representative 
data from at least three independent experiments are shown. Error bars represent the SEM of the mean in (G) and the SD of the mean from 
at least three replicates in (B, D, E and I). Arrows indicate invasive growth. Scale bar in (F and J) = 50μm. * indicates p<0.05.
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Figure 2: S100A4 expression patterns in non-small cell lung carcinoma. A-D. Examples of negative (A), weak (B), moderate 
(C), and strong (D) S100A4 expression in non-small cell lung cancers (left panels), with corresponding hematoxylin and eosin stained 
(H&E) sections (right panels). Magnification = 200X for all images.
Figure 3: S100A4 is overexpressed in lung adenocarcinoma, where it associates with decreased overall survival. A-D. 
Using semi-quantitative IHC data from our TMA, we found that S100A4 levels were significantly elevated in adenocarcinoma (ADC) when 
compared to squamous cell carcinoma (SCC, A), which was confirmed using an external gene expression dataset (B). In patients with lung 
adenocarcinoma, elevated expression of S100A4 (>2.5) correlated with shorter median survival (C). A significant relationship between 
elevated S100A4 expression and overall survival was not identified when examining all histologic subtypes (NSCLC) combined (D).
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Table 1: Clinico-pathologic parameters and S100A4 expression in lung adenocarcinoma patients
S100A4 High (>2.5) S100A4 Low (≤2.5) P value
Adenocarcinoma 17/81 (21%) 64/81 (79%)  
Age at diagnosis  
≥ 65 years 10/38 (26%) 28/38 (74%) P = 0.2893
< 65 years 7/43 (16%) 36/43 (84%)  
Collaborative Stage  
Stage I-II 10/53 (19%) 43/53 (81%) P = 0.5556
Stage III-IV 6/24 (25%) 18/24 (75%)  
Lymph node metastasis  
N0 10/50 (20%) 40/50 (80%) P = 0.7731
N1 or N2 6/26 (23%) 20/26 (77%)  
Lymphovascular invasion  
Present 10/25 (40%) 15/25 (60%) P = 0.0080
Absent 7/56 (12.5%) 49/56 (87.5%)  
Pleural Invasion  
Present 6/33 (18%) 27/33 (82%) P = 0.7825
Absent 11/48 (23%) 37/48 (77%)  
S100A4. To analyze the specific contribution of S100A4 
to anti-tumor activity of niclosamide, we performed an 
invasion assay as we did in Figure 1I on H1299 cells stably 
expressing a bicistronic S100A4-pIRES-EGFP vector 
in the presence and absence of nicosamide. In this assay 
S100A4 expression level is not subject to regulation by 
niclosamide. We found that overexpressing S100A4 did 
not prevent the inhibitory effect of niclosamide, instead, 
niclosamide significantly inhibited S100A4-mediated 
invasion to the basal level (Supplementary Figure 4). These 
results suggest that niclosamide inhibited lung cancer 
cell invasive potential is not only limited to suppression 
of S100A4 expression but also extended to inhibition of 
S100A4 signaling-mediated function.
Inhibition of S100A4 decreases NF-κB activity
Considerable evidence demonstrates that NF-
κB signaling is constitutively activated in solid tumors 
and is essential for lung cancer tumorigenesis, invasion 
and metastasis [17]. S100A4 has been shown to affect 
canonical NF-κB signaling through cross-talk with RAGE, 
TLR-4 and EGFR. In the canonical NF-κB pathway, p65 
(RelA) and p50 form a heterodimer that is sequestered by 
IkB-α under unstimulated conditions. Stimulation with 
cytokines, such as TNF-α, activates the IkB kinase (IKK) 
complex, which phosphorylates IkB-α, leading to its 
degradation. NF-κB is then released, phosphorylated and 
translocated into the nucleus where it activates a variety of 
genes that promote cell proliferation, survival and invasion 
[18, 19]. To test whether depletion of S100A4 inhibits 
the NF-κB pathway, we evaluated NF-κB activity using 
a luciferase activity assay and p65 nuclear translocation. 
Control (shCont) and S100A4 knockdown (shS100A4) 
A549 cells were transfected with an NF-κB luciferase 
reporter gene construct and treated with 5 ng/ml TNF-α. 
As shown in Figure 5A, knockdown of S100A4 not only 
decreased TNF-α induced NF-κB activity, but also reduced 
the basal activity of NF-κB. We then investigated whether 
depletion of S100A4 inhibits p65 nuclear translocation. As 
shown in Figure 5C, knockdown of S100A4 in A549 cells 
decreased p65 nuclear localization in response to TNF-α 
treatment. To determine the biological consequences 
of NF-κB inhibition, a Matrigel invasion assay was 
performed with TNF-α as the attractant in A549 shCont 
and shS100A4 cells. We observed that cells with S100A4 
knockdown (shS100A4) displayed decreased invasive 
potential (Supplementary Figure 3). Since niclosamide 
treatment suppressed S100A4 expression and decreased 
the invasive potential of lung cancer cells (Figure 4), we 
hypothesized that treatment with niclosamide would block 
NF-κB activity. To test this hypothesis, we performed 
an NF-κB luciferase activity assay and p65 nuclear 
translocation in response to TNF-α with and without 
niclosamide treatment. Niclosamide treatment decreased 
NF-κB luciferase activity and inhibited p65 nuclear 
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translocation in A549 cells (Figure 5B and 5D). Similar 
results were seen using H460 cells (data not shown). 
Taken together, these data show that S100A4 drives lung 
cancer invasion by activating NF-κB activity. These data 
also suggest that the inhibitory effect of niclosamide on 
NF-κB activity could be, at least in part, due to S100A4 
suppression.
S100A4 is required for TNF-α-induced and  
NF- κB-mediated MMP9 expression
TNF-α induces MMP9 expression through the NF-
κB pathway [20]. We tested whether inhibition of S100A4 
affects downstream targets of NF-κB such as MMP9. 
We used Q-PCR to assess the expression of MMP9 in 
Figure 4: Niclosamide decreases S100A4 expression, lung cancer cell proliferation, invasion and invasive growth. 
A and B. A549 cells were treated with niclosamide at the indicated concentrations for 72 hrs, and S100A4 expression was assessed 
by Q-PCR (A) or immunoblotting analysis (B). C and D. Cells were treated with varied concentrations of niclosamide for 1-5 days 
and then cell number assessed by either direct cell count (C, H358) or MTT assay at various time intervals (D, A549). E. A549 cells 
were treated with niclosamide at the indicated concentrations for 3 days, trypsinized and assessed for EGF-stimulated (5 ng/ml) Matrigel 
invasion in the presence or absence of niclosamide. F, G. A549 cells were cultured in 3D Matrigel with or without 1 μM niclosamide for 
6 days. Representative phase contrast images are shown (F). The diameter of 70-120 colonies from randomly chosen fields was measured, 
quantified for average individual colony volume (G). Representative data from at least three independent experiments are shown. Error bars 
represent the SEM of the mean in (G) and the SD of the mean from at least three replicates in (A, C, D and E). Scale bar in (F) = 100 μm. 
* indicates p<0.005. ** indicates p<0.0001.
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A549 shCont and shS100A4 cells with and without 
TNF-α. Knockdown of S100A4 significally decreased 
basal expression of MMP9 in H358 (Supplementary 
Figure 2C) and A549 cells as well as TNF-α-induced 
MMP9 expression (Figure 6A). In addition, niclosamide 
treatment, which decreases S100A4 expression (Figure 
4) and NF-κB activity (Figure 5), results in a significant 
inhibiton of TNF-α-induced MMP9 expression in A549 
cells (Figure 6B). Collectively, these data support the 
assertion that S100A4 confers an invasive phenotype, at 
least in part, through the NF-κB pathway. To substantiate 
the finding that MMP9 expression depends on NF-κB, we 
blocked the NF-κB pathway by using the NF-κB inhibitor, 
wedelolactone, which directly inhibits the phosphorylation 
and degradation of IκBα, and by reducing RelA (p65) 
expression using a lentiviral-based shRNA. As shown in 
Figure 6C, pretreatment of A549 cells with wedelolactone 
prior to stimulation with TNF-α dramatically decreased 
MMP9 expression. Efficient RelA knockdown 
significantly abrogated TNF-α-induced MMP9 expression 
(Figure 6D and 6E).
The NF-ĸB/MMP9 pathway is critical to the 
invasive potential of NSCLC cells
Our data demonstrate that S100A4 drives the 
invasive capacity of lung cancer cells, affects the NF-κB 
pathway, and acts as an essential component of TNF-α-
induced and NF-κB-dependent MMP9 expression. Next, 
we investigated whether the NF-κB/MMP9 axis is critical 
to the invasive capacity of lung cancer cells. Accordingly, 
we pretreated A549 cells with inhibitors of either NF-
κB or MMP2/MMP9, then performed Matrigel invasion 
assays. Inhibition of the NF-κB/MMP9 pathway not only 
decreased the basal invasive capacity but also inhibited 
cell invasion toward chemo-attractants such as TNF-α 
and EGF (Figure 6F). Collectively, these results implicate 
S100A4 in driving lung cancer invasive potential, at least 
in part, through activation of the NF-κB/MMP9 axis.
Figure 5: Inhibition of S100A4 decreases NF-κB activity. A and B. A549 shCont and shS100A4 cells (A) or A549 parental cells 
(B) were transfected with NF-κB firefly luciferase reporter and TK-renilla luciferase control, treated with 5 ng/ml TNF-α with or without 
niclosamide at indicated concentrations for 24 hrs before harvesting for Dual luciferase activity assays. C. A549 shCont and shS100A4 
cells (C) were serum starved overnight, then stimulated with 5 ng/ml TNF-α for 4 hrs before harvesting for cell fractionation. D. A549 
parental cells were treated with 0.5 μM niclosamide for 48 hrs, serum starved in the presence or absence of niclosamide overnight, then 
stimulated with 5 ng/ml TNF-α for 4 hrs before harvesting for cell fractionation. Nucleic and cytosolic proteins were separated by SDS-
PAGE, transferred and probed for p65, p84 and GAPDH. Representative data from at least three independent experiments are shown. Error 
bars represent the SD of the mean from three replicates. (*) and (#) in (A) indicate p<0.05 compared to control and TNF-α treated shCont 
cells, respectively. (*) and (#) in (B) indicate p<0.001 compared to control and TNF-α treated cells, respectively.
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DISCUSSION
The majority of patients with advanced NSCLC 
die within 18 months of diagnosis, usually as a result of 
metastatic disease [21, 22]. Elucidation of the mechanisms 
driving lung cancer invasion and metastasis can lead to 
the development of therapies targeting these pathways 
which, in turn, will have significant impacts on patient 
survival and quality of life. S100A4 is known to promote 
aggressive behavior in human cancers [6] and can be 
induced by cigarette smoke [Monzon ME, et.al., Am J 
Resp Crit Care. 2011; 183. Meeting Abstract]. S100A4 is 
often overexpressed in NSCLC as well as other tobacco-
related malignancies, making it an excellent therapeutic 
target for lung and other cancers. As published in other 
reports [23, 24], we found that S100A4 expression was 
elevated in lung adenocarcinoma. However, due to 
the small sample size and lack of non-smokers in our 
population, we could not confirm an association between 
S100A4 expression and tobacco exposure. We found 
that in lung adenocarcinoma patients, S100A4 elevation 
was associated with reduced overall survival as well as 
lymphovascular invasion, a marker of poor prognosis in 
many cancers. A similar association between elevated 
S100A4 expression and lymphovascular invasion has 
previously been demonstrated in colorectal carcinoma 
[25]. Taken together, these data suggest that S100A4 could 
serve as a marker of poor prognosis as well as a valuble 
therapeutic target in lung cancer.
It is well established that S100A4 overexpression 
contributes to several hallmarks of cancer. Supported 
by a previous study [26], we found that depletion of 
S100A4 inhibited cell proliferation in both H358 and 
A549 cells. However, forced expression of S100A4 
alone in H1299 cells is not sufficient to promote cell 
proliferation, suggesting that the role of S100A4 in cell 
proliferation could be cell context dependent. Recent 
studies demonstrate that S100A4 promotes lung cancer 
cell mortility and cell growth [27], although the detailed 
mechanisms have not been fully defined. Notably, 
Figure 6: The S100A4/NF-κB/MMP9 axis is critical to the invasive capacity of lung cancer cells. A-C. Cells were exposed 
to a variety of experimental conditions and then TNF- α was added for an additional 24 hrs prior to assessment of MMP9 expression by 
Q-PCR. A549 shCont and shS100A4 cells treated with 5 ng/ml TNF-α for 24 hrs (A), or parental A549 cells were pretreated with 1μM 
niclosamide for 48 hrs (B), or parental A549 cells treated with 10 μM and 50 μM Wedelolactone (WEL) for 24 hrs (C). D-E. A549 shCont 
and shRelA cells were treated with 5 ng/ml TNF-α for 24 hrs, then harvested and assessed for MMP9 (D) and RelA (E) expression by 
Q-PCR. F. Parental A549 cells were pretreated with 10 μM Wedelolactone or 100 μM MMP2/9 inhibitor I for 24 hrs, trypsinized, rinsed 
and assessed for Matrigel invasion toward 5 ng/ml TNF-α or 5 ng/ml EGF overnight in the presence or absence of the respective inhibitors. 
Representative data from at least three independent experiments are shown. Error bars represent the SD of the mean from three replicates.* 
indicates p<0.05, ** indicates p<0.01.
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extracellular S100A4 has been shown to activate canonical 
NF-κB pathway through activation of IκB-α [10, 28–31]. 
NF-κB signaling is constitutively activated in solid tumors 
including lung cancer [32] and is essential for lung cancer 
tumorigenesis, invasion and metastasis [17]. Although NF-
κB has been considered as a therapeutic target, its role in 
normal physiology poses a substantial challenge for directly 
targeting NF-κB for cancer therapy. Therefore, alternatively 
targeting the upstream or downstream pathways that lead to 
constitutive NF-κB activation may be more sucessful [33]. 
Our data demonstrated that inhibition of S100A4 decreased 
NF-κB p65 nuclear translocation in response to TNF-α. 
We also found that depletion of S100A4 decreased the 
basal activity of NF-κB signaling. Inhibition of the NF-κB 
pathway dramatically blocked the invasive capacity of lung 
cancer cells, suggesting that inhibition of S100A4 signaling 
could effectively mitigate NF-κB-mediated effects.
Matrix metalloproteinases (MMPs) are essential 
in tumor invasion and metastasis due to their abilities 
to degrade the extracellular matrix (ECM) and also 
to change cellular behavior to modulate the tumor 
microenvironment. Downstream of the NF-κB pathway, 
we found that MMP9, but not MMP2, was dramatically 
inhibited by S100A4 depletion in response to TNF-α (data 
not shown). Importantly, MMP9 inhibition decreased the 
TNF-α- and EGF-stimulated invasiveness of A549 cells, 
highlighting the importance of the S100A4/MMP9 axis in 
S100A4-driven invasion in lung cancer cells. Given that 
S100A4 is an established metastasis-promoting protein, 
it is not surprising that this S100A4/MMP9 pathway is 
demonstrated in other cancer types [34]. In support of 
our study, recent work has shown that both S100A4 and 
MMP9 are upregulated in patient-derived lung cancer 
tissues and positively correlate with each other [23], 
further implicating the importance of S100A4/MMP9 
signaling in lung cancer progression.
Currently, there is no clinically available treatment 
targeting S100A4 and its pleiotropic roles in cancer 
progression. Multiple strategies have been proposed to 
block S100A4 function in cancer. These strategies include 
targeting S100A4 with specific antibodies or interfering 
with the interaction of S100A4 and its targets using 
small molecular inhibitors [35, 36]. However, S100A4 
is often present at high concentrations in malignancies, 
and is also high in inflammatory disorders [37, 38], which 
complicates the use of antibodies to inhibit S100A4 
signaling extracellularly and/or through blocking the 
intracellular action. Niclosamide, an anti-helminthic 
agent used for over 50 years to treat tapeworm infections 
in humans, is proposed to have a favorable safety profile 
due to poor systemic absorption from the gastrointestinal 
tract [15]. However, animal studies have shown that 
the concentration of niclosamide in tumor tissue and 
plasma can reach up to 1 μM, thus revealing that it is 
readily absorbed without significant toxicity to normal 
fibroblasts and peripheral blood mononuclear cells [15, 
39]. Niclosamide inhibits S100A4 through the Wnt/β-
catenin pathway in colon cancer [16]. Our study extends 
current understanding by showing that at physiologically 
achievable levels, niclosamide can effectively target the 
S100A4/NF-κB/MMP9 signaling axis in lung cancer by 
decreasing S100A4 expression. This decrease in S100A4 
expression in turn decreases NF-κB activity and NF-
κB-mediated MMP9 expression. Given that S100A4 
is secreted and can be detected in patient serum, our 
study suggests that S100A4 could be used as a potential 
biomarker to monitor the response to niclosamide 
treatment, although in vivo studies are needed to confirm 
this concept.
Our study highlights the important role of the 
S100A4/NF-κB/MMP9 signaling axis in promoting lung 
cancer invasive capacity, and demonstrates that S100A4 
overexpression associates with reduced overall survival 
among patients with lung adenocarcinoma. Importantly, 
our study demonstrates that niclosamide dramatically 
inhibits the NF-κB/MMP9 signaling axis by suppressing 
S100A4 to block the invasive capacity of lung cancer cells. 
Since S100A4 promotes metastasis, our study provides 
strong evidence and rationale for targeting S100A4 by 
repurposing niclosamide to block invasion and prevent 
metastasis in NSCLC.
MATERIALS AND METHODS
Cell lines and reagents
Lung cancer cell lines that are representative of 
different subtypes of lung cancer were obtained from 
ATCC. Lung adenocarcinoma (A549, EKVX, H358, 
Hop62, H322M, H522, H838, and H23), large cell lung 
carcinoma (H460, Hop92), NCSLC (H1299, H810) 
and small cell lung cancer (H82) cell lines were used in 
this study. A549, H1299, H358 and H460 cells used for 
biological functional analysis were authenticated with 
short tandem repeat (STR) profile analysis by Genetica 
DNA laboratories in May 2015. Niclosamide and 
Wedelolactone were obtained from Sigma-Aldrich (St. 
Louis, MO). MMP2/9 inhibitor I was from Calbiochem/
EDM Millipore (Billerica, MA). The pIRES-GFP-S100A4 
construct was obtained from Dr. Masashi Fukayama 
(University of Tokyo, Tokyo, Japan) [40].
Immunoblotting
Cells were harvested and lysed in RIPA buffer (150 
mM NaCl, 0.5 mM EGTA, 0.5% sodium deoxycholate, 
0.1% SDS, 1% Triton X-100, 50 mM Tris-HCl pH 7.4, 
15 μg/ml protease inhibitor cocktail, 1 mM PMSF, 50 
mM NaF and 10 mM sodium pyrophosphate). Total cell 
lysates (80 μg) were subjected to 10% or 15% SDS-PAGE, 
transferred and immunoblotted with rabbit anti-S100A4 
antibody (Dako, Carpinteria, CA), p65 (Santa Cruz, 
Oncotarget34639www.impactjournals.com/oncotarget
Dallas, TX) or p84 (GeneTex, Irvine, CA). Tubulin and 
β-actin antibodies were from Sigma-Aldrich and were 
used as the loading controls.
Three-dimensional (3D) culture
Culturing lung cancer cells in 3D was performed as 
described previously [14]. Briefly, cells (1 x 104) in 200 μl 
growth media with 2% FBS were seeded onto solidified 
growth factor-reduced Matrigel (BD Biosciences, San 
Jose, CA; 100 μl per well of 8-well chamber slide) and 
then covered with medium containing 10% Matrigel. 
The next day, DMSO or niclosamide at the indicated 
concentration was added to the cultures. When the control 
cells developed an invasive growth phenotype (approx. 
5-6 days), phase contrast images of randomly chosen 
fields were taken with a Nikon Ti-E inverted microscope 
and analyzed using Nikon Elements software.
Matrigel invasion assay
Matrigel (10 μg, BD Biosciences) was dried onto the 
upper well of transwell chambers (6.5-mm diameter, 8-μm 
pore size, Corning, Corning, NY). One hour before the 
assay, Matrigel was reconstituted with 100 μl of serum-
free medium and the bottom chamber was coated with 5 
μg/ml fibronectin. Cells (70% confluent) were trypsinized 
and rinsed three times with serum-free medium plus 
250 μg/ml BSA. Cells (5x104) were added to the upper 
chamber, and medium/BSA containing 5 ng/ml EGF, 
5 ng/ml TNF-α or 1% FBS (control) was added to the 
bottom chamber as indicated; cells were allowed to invade 
overnight at 37°C. Non-invaded cells were removed from 
the top chamber using a cotton swab; invaded cells on the 
bottom of the transwell membrane were fixed with 100% 
methanol and stained with 1% crystal violet. Four fields 
per well were counted and averaged, and the data were 
presented as the mean number of cells invaded per mm2 
+/- standard deviation from triplicate determinations.
Cell proliferation assays
Cell proliferation was assessed by direct cell 
counting or by 3-(4, 5-dimethylthiazol-2-yl)-2.5-
diphenyltetrazolium bromide (MTT) assay. Cells (0.5 
x105) were seeded in each well of a 12-well plate for 
direct cell counting or cells (2x103) were seeded in each 
well of a 96-well plate for MTT assay. For niclosamide 
treatment, fresh growth media containing niclosamide 
or DMSO was added starting the day after plating, and 
added daily thereafter. Cells were trypsinized and directly 
counted by using a Vi-Cell XR cell viability counter 
(Beckman Coulter, Brea, CA) at the indicated time points. 
Alternatively, MTT assay was performed as previously 
described [41].
Quantitative real time PCR (Q-PCR)
Total RNA was extracted using TRizol reagent (Life 
Technologies/ThermoFisher, Grand Island, NY). Total 
RNA (1μg) was used to reverse-transcribe into cDNA 
using the High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems/ThermoFisher, Grand Island, NY). 
Expression of target genes was assessed by Comparative 
Ct (∆∆Ct) using commercially available probes and 
master mix reagent and performed on a StepOnePlusTM 
96-well instrument as described by the manufacturer 
(Applied Biosystems). The expression level of each gene 
was normalized by 18S or β-actin RNA and reported as a 
relative level to a specified control, as noted.
Stable lentiviral shRNA cell line generation
For stable reduction of S100A4 expression in A549 
and H460 cells, lentivirus-mediated shRNA construct 
pLKO.1-puro targeting human S100A4 (S100A4-#A6) 
or containing non-targeting sequence (Sigma-Aldrich) 
were packaged into virus. In brief, the control or 
S100A4-specific shRNA construct was co-transfected with 
Mission lentiviral packaging mix (Sigma-Aldrich) into 
293T cells using polyethylenimine (PEI) based on 1:3 ratio 
of DNA: PEI. The viral supernatant was collected 48 hrs 
after transfection, as described previously [7]. Then, A549 
and H460 cells were infected with virus containing media 
and stable transfectants were selected with puromycin 
(2 μg/ml). The targeting sequences for human S100A4 
are 5’ AAGCTCAACA AGTCAGAACT AAA (#A6) and 
5’CGCCATGATGTGTAACGAATT 3’ (#A8).
Generation of S100A4 overexpression cell lines
H1299 cells in 10-cm dishes were transfected with 8 
μg GFP control or pIRES-GFP-S100A4 constructs using 
Lipofectamine 2000 (Invitrogen/ThermoFisher, Grand 
Island, NY). Transfected cells were selected with G418 
(400 μg/ml) and sorted for GFP by fluorescence activated 
cell sorting (FACS).
Tissue microarray (TMA) construction and 
immunohistochemistry (IHC) staining
Institutional Review Board Approval (13-0692-
P6H) was obtained prior to initiation of the project. 
Surgically resected NSCLC cases from 2006-2010 from 
our institution were screened for inclusion in this study. 
Cases were excluded if the primary tumor was not of lung 
origin or if inadequate pathological material existed. A 
total of 216 lung cancer cases were used to build the tissue 
microarrays (TMAs). A variety of histologic types were 
selected, including 83 adenocarcinomas and 102 squamous 
cell carcinomas (for complete list see Supplementary 
Oncotarget34640www.impactjournals.com/oncotarget
Table 2). Pathologic features (tumor grade, histologic type, 
presence of lymphovascular invasion etc.) were abstracted 
from pathology records and patient charts. Treatment 
and outcome data were collected by the Markey Cancer 
Center (MCC) Cancer Research Informatics Shared 
Resource Facility and the Kentucky Cancer Registry. 
Our pathologist then selected appropriate blocks and 
identified tumor areas on H&E stained slides for inclusion 
in the TMA. For each case, three 2-mm tissue cores were 
removed from each formalin-fixed, paraffin embedded 
(FFPE) archival tumor block, and were transferred to 
recipient paraffin blocks using a TMArrayer TM (Pathology 
Devices, Westminster, MD). Listing of randomly-sorted 
samples for allocation into the recipient TMA was 
generated by the MCC Biostatistics and Bioinformatics 
Shared Resource Facility, and then assembled into TMA 
blocks (12 in total) by the MCC Biospecimen and Tissue 
Procurement Shared Resource Facility. After construction, 
TMA blocks were heated at 45° C for 1 hr and then cooled 
to complete assembly. S100A4 expression was assessed 
by IHC staining as previously reported [7, 42] and scored 
by a pathologist blinded to clinical variables. Out of 216 
cases included in the TMA, 4 were excluded from analysis 
due to folded or absent tissue cores. In the remaining 212 
cases, a semi-quantitative scale was used to score S100A4 
expression as follows: negative (0), weakly positive (1), 
moderately positive (2), and strongly positive (3) (Figure 
2). Results from each of the three tissue cores were 
averaged together to produce a final score for each tumor. 
S100A4 overexpression was defined as a final score >2.5.
NF-κB activity assays
For NF-κB luciferase reporter assays, cells grown 
in a 24-well plate were co-transfected with 0.25 μg of the 
NF-κB reporter (A gift from Dr. Yanan Tian, Texas A& M 
University) along with pRL-TK Renilla control reporter 
at a 50:1 ratio for 24 hrs. Then, cells were induced by 5 
ng/ml TNF-α, vehicle control with or without niclosamide 
at the indicated concentration for 24 hrs. Then, cells were 
collected and luciferase activity was measured using 
the Dual-Luciferase Reporter Assay System (Promega, 
Madison, WI). These data are presented as a relative value 
to internal control or fold induction as individual control.
To detect NF-κB p65 nuclear translocation, cells 
were serum-starved overnight and then stimulated with 
5 ng/ml of TNF-α for 4 hrs. For niclosamide treatment, 
cells were pretreated with DMSO (control) or 0.5 μM 
or 1 μM niclosamide for 48 hrs before serum starvation, 
then stimulated with 5 ng/ml of TNF-α for 4 hrs. Cell 
fractionation was then performed as described previously 
[41].
Statistical analysis and data mining
For quantitative variables, differences between 
groups were analyzed using Welch’s t-test or the Mann–
Whitney U test, where appropriate. For categorical 
variables, differences between groups were analyzed using 
chi-squared or Fisher’s exact test, where appropriate. All 
tests were two-tailed. Survival differences were assessed 
via log-rank test. Significance was reached when P < 
0.05. Statistical analyses were performed using GraphPad 
software (La Jolla, CA). For data mining, a lung cancer gene 
expression dataset [43] generated by The Cancer Genome 
Atlas (TCGA Research Network, http://cancergenome.nih.
gov/) was accessed and visualized using The Oncomine™ 
Platform (Life Technologies, Ann Arbor, MI).
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